You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-LRRK2 antibodySee all LRRK2 primary antibodies ...
  • Description
    Goat polyclonal to LRRK2
  • Tested applicationsIHC-P, IHC-Fr, WB more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    A synthetic peptide, to an internal region of Human LRRK2 conjugated to an immunogenic carrier protein.

Properties

Applications

Our Abpromise guarantee covers the use of ab104614 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
IHC-P IHC-P: 1/200 - 1/2000. Antigen retrieval is recomended before commencing with IHC staining protocol
IHC-Fr IHC-Fr: 1/200 - 1/2000.
WB WB: 1/200 - 1/2000. Predicted molecular weight: 286 kDa. This antibody has been tested in Western blot against the recombinant peptide used as an immunogen. We have no data on detection of endogenous protein.

Target

  • FunctionMay play a role in the phosphorylation of proteins central to Parkinson disease. Phosphorylates PRDX3. May also have GTPase activity. Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes.
  • Tissue specificityExpressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
  • Involvement in diseaseParkinson disease 8 (PARK8) [MIM:607060]: A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients. Note=The disease is caused by mutations affecting the gene represented in this entry.
  • Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.
    Contains 12 LRR (leucine-rich) repeats.
    Contains 1 protein kinase domain.
    Contains 1 Roc domain.
  • Post-translational
    modifications
    Autophosphorylated.
  • Cellular localizationCytoplasm. Membrane. Mitochondrion. Localized in the cytoplasm and associated with cellular membrane structures. Associates with the mitochondrial outer membrane.
  • Target information above from: UniProt accession Q5S007 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      augmented in rheumatoid arthritis 17 antibodyAURA17 antibodyDardarin antibody
      Leucine rich repeat kinase 2 antibodyLeucine-rich repeat serine/threonine-protein kinase 2 antibodyLRRK 2 antibodyLRRK2 antibodyLRRK2_HUMAN antibodyPARK 8 antibodyPARK8 antibodyRIPK7 antibodyROCO 2 antibodyROCO2 antibody
    see all

References for Anti-LRRK2 antibody (ab104614)

ab104614 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab104614.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"